HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 06, June 2017 – Advocacies in Support of Rare Disease Patients       » Bayer and NUS Enterprise Announce Winners of Grants4Apps? Singapore Open Innovation Challenge       » Cancer Control Efforts in Vietnam: Interview with Dr Tran Thanh Huong       » China Sets up National Lab Developing Brain-Like AI Technology       » New Womb-Like Invention for Preterm Infants       » World Asthma Day: Managing and Living with Asthma       » Managing Liver Cancer as a Global Health Problem      
BIOBOARD - INSIDE INDUSTRY
Nagasaki University and Astellas launch collaborative research for screening new anti-dengue virus drugs for neglected tropical diseases
The Nagasaki University and Astellas Pharma Inc. announced that they have signed a collaborative research agreement to discover new drugs for the treatment of neglected tropical diseases ("NTDs") caused by dengue virus. This is the second execution of a collaborative research agreement on NTDs after the Nagasaki University and Astellas signed the previous one to discover new drugs for the treatment of NTDs caused by protozoan parasites on November 12, 2012.

NTDs, prevalent mainly in tropical areas of developing countries, are infectious diseases spread by parasites, bacteria or viruses. As it is estimated that approximately 1 billion people are affected with NTDs worldwide, NTDs are a serious healthcare issue that is being addressed on a global scale. Among them, diseases caused by dengue virus, such as dengue fever/dengue hemorrhagic fever are with high unmet medical needs for treatment and development of new therapeutic drugs. There is no existing drug to treat dengue fever/dengue hemorrhagic fever in the market as well as under development, and the effectiveness of some vaccines to prevent dengue virus currently under development is unclear at this time.

Under the collaborative agreement, the Institute of Tropical Medicine at Nagasaki University (NEKKEN), which is one of the leading research institutes on tropical infectious diseases in Japan, and Astellas will cooperate on a drug-discovery research project. Astellas will provide multiple compounds with possible anti-dengue virus activities, and NEKKEN will evaluate these compounds in experimental model of infections with dengue virus for dengue fever/dengue hemorrhagic fever. The research will be advanced with advice from Professor Kouichi Morita, M.D., Ph.D., at the Department of Virology in NEKKEN, who is a key opinion leader on tropical infection research in Japan.

The collaborative research is largely divided into two phases. In the first phase (first screening), the anti-dengue virus activities and cytotoxic activities of compounds will be measured in vitro. In the second phase (second screening), compounds found to be with anti-dengue virus activities in the first screening will be tested for in vivo activity by evaluating drug efficiency in animals infected with the dengue virus.

The Nagasaki University and Astellas will work together to accelerate the discovery of new drugs for patients suffering from dengue fever/dengue hemorrhagic fever in the world, through their collaborative research aiming to contribute to improve global public health problems.

Click here for the complete issue.

NEWS CRUNCH  
news The Seventh International Meeting on Synthetic Biology (SB 7.0)
news Healthcare Sustainability in Asia: Now is the Time to Act — FT Asia Healthcare & Life Sciences Summit 2017
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy